Epiendo Pharmaceuticals
Clinical trials sponsored by Epiendo Pharmaceuticals, explained in plain language.
-
New drug EP395 shows promise in taming lung inflammation
Disease control CompletedThis study tested a new drug called EP395 in 49 healthy adults to see if it could reduce inflammation in the lungs. Participants inhaled a substance that causes temporary airway inflammation, and those who received EP395 were expected to have less inflammation than those who rece…
Phase: PHASE1 • Sponsor: EpiEndo Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New drug EP395 tested in healthy adults to see how it affects lung inflammation
Knowledge-focused CompletedThis study tested an experimental drug called EP395 in 40 healthy adults. Researchers used a safe, temporary lung inflammation model (inhaled endotoxin) to see how the drug affects immune markers and to check its safety. The goal was to gather early information, not to treat a di…
Phase: PHASE1 • Sponsor: EpiEndo Pharmaceuticals • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC
-
New drug EP395 tested for safety in healthy people
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of a new drug called EP395 in 78 healthy adults aged 18 to 65. Participants received single or multiple doses of the drug in capsule form. The goal was to find a safe dose range for future research.
Phase: PHASE1 • Sponsor: EpiEndo Pharmaceuticals • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC
-
New COPD drug safety checked in healthy volunteers
Knowledge-focused CompletedThis study looked at how a new medicine called EP395, being developed for COPD, interacts with other common drugs. Healthy adults aged 18 to 55 took part to see how EP395 levels change when taken with verapamil, and how EP395 affects midazolam and digoxin. The goal was to gather …
Phase: PHASE1 • Sponsor: EpiEndo Pharmaceuticals • Aim: Knowledge-focused
Last updated May 07, 2026 18:42 UTC